% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Risse:57304,
      author       = {Risse, J. H. and Rabe, C. and Pauleit, D. and Reichmann, K.
                      and Menzel, C. and Grünwald, F. and Strunk, H. and
                      Biersack, H.-J. and Palmedo, H.},
      title        = {{T}herapy of hepatocellular carcinoma with
                      iodine-131-lipiodol: results in a large {G}erman cohort},
      journal      = {Nuklearmedizin},
      volume       = {45},
      issn         = {0029-5566},
      address      = {Stuttgart},
      publisher    = {Schattauer},
      reportid     = {PreJuSER-57304},
      pages        = {185 - 192},
      year         = {2006},
      note         = {Record converted from VDB: 12.11.2012},
      abstract     = {Aim: To evaluate the efficacy and tolerance of
                      iodine-I-131-lipiodol (I-131-lipiodol) for hepatocellular
                      carcinoma (HCC) in German long term patients and comparison
                      with medically treated controls. Patients, Methods: 38
                      courses of intro-arterial I-131-lipiodol therapy with a
                      total activity up to 6.7 GBq were performed in 18 patients
                      with HCC (6 with portal vein thrombosis). Liver and tumour
                      volume and lipiodol deposition were measured by computed
                      tomography and I-131 activity by scintigraphy. Therapeutic
                      efficacy was determined by tumour volume change and
                      matched-pairs analysis in comparison to medically (i.e.
                      tamoxifen or medical support) treated patients. Results:
                      Tumour volume decreased in 20/32 index nodules $(63\%)$
                      after the first course. Repeated therapy frequently resulted
                      in further tumour reduction. Overall response to treatment
                      was partial in 11 nodules, minor response in 4 nodules, and
                      disease was stable in 12 and progressive in 5. Significant
                      response was associated with pretherapeutic nodule volume up
                      to 150 ml (diameter of 6.6 cm). Survival rate after 3, 6, 9,
                      12, 24 and 36 months was 78, 61, 50, 39, 17, and $6\%.$
                      Matched-pairs analysis of survival revealed I-131-lipiodol
                      to be superior to medical treatment. The most important side
                      effect was a pancreatitis-like syndrome whereas overall
                      tolerance was good. Conclusion: The long term results
                      confirm that HCC therapy with I-131-lipiodol is effective
                      and probably superior to medical treatment. Tumour nodules
                      of up to 6 cm diameter are well suited for this therapy even
                      in the presence of portal vein thrombosis.},
      keywords     = {J (WoSType)},
      cin          = {IME},
      ddc          = {610},
      cid          = {I:(DE-Juel1)VDB54},
      pnm          = {Funktion und Dysfunktion des Nervensystems},
      pid          = {G:(DE-Juel1)FUEK409},
      shelfmark    = {Radiology, Nuclear Medicine $\&$ Medical Imaging},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000239765700008},
      url          = {https://juser.fz-juelich.de/record/57304},
}